LLY

718.97

-2.33%↓

JNJ

152.31

-1.21%↓

ABBV

181.63

-0.89%↓

NVO

67.98

-2.07%↓

UNH

302.1

-1.61%↓

LLY

718.97

-2.33%↓

JNJ

152.31

-1.21%↓

ABBV

181.63

-0.89%↓

NVO

67.98

-2.07%↓

UNH

302.1

-1.61%↓

LLY

718.97

-2.33%↓

JNJ

152.31

-1.21%↓

ABBV

181.63

-0.89%↓

NVO

67.98

-2.07%↓

UNH

302.1

-1.61%↓

LLY

718.97

-2.33%↓

JNJ

152.31

-1.21%↓

ABBV

181.63

-0.89%↓

NVO

67.98

-2.07%↓

UNH

302.1

-1.61%↓

LLY

718.97

-2.33%↓

JNJ

152.31

-1.21%↓

ABBV

181.63

-0.89%↓

NVO

67.98

-2.07%↓

UNH

302.1

-1.61%↓

Search

Minerva Neurosciences Inc

Atidarymo kaina

1.4 2.94

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.37

Max

1.5

Pagrindiniai rodikliai

By Trading Economics

P/E

Sektoriaus vid.

7

54.533

Darbuotojai

8

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+244.83% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-4.6M

8.3M

Ankstesnė atidarymo kaina

-1.54

Ankstesnė uždarymo kaina

1.4

Minerva Neurosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-21 23:25; UTC

Karštos akcijos

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

2025-05-21 21:57; UTC

Įsigijimai, susijungimai, perėmimai

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

2025-05-21 21:29; UTC

Įsigijimai, susijungimai, perėmimai

Millicom to Acquire Telefónica's Operations in Uruguay

2025-05-21 21:01; UTC

Pagrindinės rinkos jėgos

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

2025-05-21 23:49; UTC

Rinkos pokalbiai

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

2025-05-21 23:37; UTC

Rinkos pokalbiai

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

2025-05-21 23:33; UTC

Įsigijimai, susijungimai, perėmimai

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

2025-05-21 23:32; UTC

Įsigijimai, susijungimai, perėmimai

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

2025-05-21 23:32; UTC

Įsigijimai, susijungimai, perėmimai

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

2025-05-21 23:32; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

2025-05-21 23:31; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

2025-05-21 23:30; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

2025-05-21 23:30; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

2025-05-21 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

2025-05-21 23:28; UTC

Uždarbis

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

2025-05-21 23:27; UTC

Uždarbis

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

2025-05-21 23:26; UTC

Uždarbis

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

2025-05-21 23:26; UTC

Uždarbis

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

2025-05-21 23:26; UTC

Uždarbis

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

2025-05-21 23:23; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

2025-05-21 23:22; UTC

Svarbiausios naujienos

Walmart to Cut 1,500 Corporate Jobs in Restructuring -- WSJ

2025-05-21 23:22; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

2025-05-21 23:20; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

2025-05-21 23:18; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

2025-05-21 23:04; UTC

Svarbiausios naujienos

EV Owners Face Annual Fee Under Proposed Tax Bill -- Barrons.com

2025-05-21 21:46; UTC

Svarbiausios naujienos

NBCUniversal Bids for MLB Rights That Were Dropped by ESPN -- WSJ

2025-05-21 21:42; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

2025-05-21 21:14; UTC

Įsigijimai, susijungimai, perėmimai

Millicom to Acquire Telefónica's Ops in Uruguay

2025-05-21 21:07; UTC

Svarbiausios naujienos

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

2025-05-21 21:06; UTC

Įsigijimai, susijungimai, perėmimai

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Minerva Neurosciences Inc Prognozė

Kainos tikslas

By TipRanks

244.83% į viršų

12 mėnesių prognozė

Vidutinis 5 USD  244.83%

Aukščiausias 5 USD

Žemiausias 5 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Minerva Neurosciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

1 ratings

0

Pirkti

1

Laikyti

0

Parduoti

Finansinės naujienos

$

Apie bendrovę Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.